Loxoprofen Sodium Market Overview
Global Loxoprofen Sodium Market size is USD 1346.06 million in 2026, set to expand to USD 2319.65 million by 2035, growing at a CAGR of 6.23%.
The Loxoprofen Sodium Market is developing as healthcare providers and pharmaceutical manufacturers address continuing demand for effective pain management, inflammation control, and treatment of musculoskeletal conditions. Tablet formulations account for 72% of the market's product segmentation, reflecting established prescription practices, convenient administration, and widespread availability within countries where loxoprofen sodium is approved. Loxoprofen sodium is a nonsteroidal anti-inflammatory drug that reduces pain and inflammation through inhibition of prostaglandin synthesis after metabolic activation.
The United States represents a limited commercial market for loxoprofen sodium compared with Japan and selected Asian countries because the medicine does not have an established United States FDA-approved prescription or over-the-counter marketing pathway. North America represents 14% of the report's analytical regional allocation, but this figure should not be interpreted as verified domestic United States loxoprofen utilization. American pain management services rely on medicines authorized under the country's regulatory framework, and loxoprofen sodium cannot be assumed to have the same market access as widely approved alternatives.
Key Findings
- Key Market Driver: Increasing demand for musculoskeletal pain relief, established prescription practices, and convenient anti-inflammatory treatment supports market activity, with Pain Management accounting for 46% of application demand.
- Major Market Restraint: Regulatory restrictions, gastrointestinal adverse effects, and renal safety considerations limit wider pharmaceutical adoption, while Capsule formulations represent 14% of the market's product segmentation.
- Emerging Trends: Compact topical patches, improved adhesive technology, and patient-oriented product design are influencing pharmaceutical development, with Patch formulations accounting for 18% of product demand.
- Regional Leadership: Asia-Pacific leads the Loxoprofen Sodium Market with 58% regional share, supported by established Japanese prescribing practices, pharmaceutical manufacturing infrastructure, and recognized therapeutic applications.
- Competitive Landscape: Daiichi Sankyo Co., Ltd. leads the selected analytical competitive allocation with 24% share, reflecting its established Loxonin product portfolio, formulation development capabilities, and Japanese market presence.
- Market Segmentation: Tablet dominates product demand with 72% share, supported by convenient oral administration, established generic manufacturing, and extensive use across approved pain management applications.
Loxoprofen Sodium Market Latest Trends
The Loxoprofen Sodium Market is increasingly influenced by patient-oriented topical formulations, improved pharmaceutical packaging, and the development of products suitable for localized musculoskeletal pain. Patch formulations account for 18% of the market's product segmentation, highlighting demand for convenient external administration among patients with selected approved indications. During March 2026, Daiichi Sankyo's healthcare business announced the introduction of Loxonin S Tape mini, a smaller topical product containing loxoprofen sodium hydrate. The product became available in Japan on April 15, 2026, with dimensions of 5 cm by 7 cm.
Another important trend involves pharmaceutical supply reliability, generic competition, and improvements in medicine administration practices. Tablet formulations represent 72% of market demand, making manufacturing consistency and product availability important commercial considerations. Towa Pharmaceutical Co., Ltd. maintains loxoprofen sodium tablet products within Japan's generic pharmaceutical environment. During June 2026, the company announced the addition of several newly listed generic medicines across its wider portfolio, demonstrating continued investment in pharmaceutical production and distribution.
Loxoprofen Sodium Market Dynamics
Driver
"Increasing musculoskeletal pain treatment requirements support established anti-inflammatory medicine demand."
The primary driver of the Loxoprofen Sodium Market is ongoing demand for medicines used to manage pain and inflammation associated with musculoskeletal disorders and other approved clinical indications. Pain Management accounts for 46% of the market's application segmentation, demonstrating the importance of symptomatic treatment within the product category. Loxoprofen sodium is used in Japan and selected other markets as a nonsteroidal anti-inflammatory medicine for appropriate conditions. Its pharmacological activity depends on conversion to an active metabolite that inhibits enzymes involved in prostaglandin production. Reduced prostaglandin synthesis contributes to the medicine's analgesic and anti-inflammatory effects. Clinicians consider the location and severity of symptoms, relevant medical history, concurrent medicines, and individual safety factors before selecting treatment. Established pharmaceutical distribution networks support access where appropriate regulatory authorizations exist. Demand for convenient oral administration also favors tablet formulations within routine clinical practice.
Restraint
"Restricted regulatory availability and recognized NSAID safety risks limit wider adoption."
A major restraint affecting the Loxoprofen Sodium Market is limited international regulatory availability combined with the known risks associated with nonsteroidal anti-inflammatory therapy. North America accounts for 14% of the report's analytical regional allocation, but the medicine does not have an established FDA-approved commercial market in the United States. Pharmaceutical products require authorization in each relevant jurisdiction before routine marketing. Approval in Japan does not automatically permit distribution elsewhere. Regulatory submissions may require appropriate pharmaceutical quality information, clinical evidence, safety evaluation, and approved labeling. Commercial demand is also influenced by the availability of alternative medicines already established within national treatment systems. Manufacturers considering geographic expansion must evaluate whether the required regulatory investment is commercially practical.
Opportunity
"Convenient topical formulations and reliable generic manufacturing create specialized growth opportunities."
One of the strongest opportunities in the Loxoprofen Sodium Market is the development of convenient dosage forms that address specific patient administration needs within approved therapeutic indications. Patch formulations represent 18% of product demand, illustrating opportunities for localized application and differentiated product design. Compact patches may be useful for patients seeking suitable treatment around smaller affected areas, provided the product's indications and safety instructions are followed. Daiichi Sankyo's April 2026 launch of Loxonin S Tape mini demonstrates this approach through a smaller adhesive format. Manufacturers can investigate improvements in patch flexibility, adhesion, packaging, and handling convenience. Product development must also consider medicine stability, skin tolerability, controlled release characteristics, and manufacturing consistency. Any new formulation requires the appropriate regulatory assessment.
Challenge
"Maintaining treatment safety and product differentiation remains challenging in established generic markets."
A central challenge in the Loxoprofen Sodium Market is maintaining appropriate pharmaceutical quality and patient safety while competing with established anti-inflammatory medicines and generic formulations. Tablet represents 72% of the market's product segmentation, making consistency of oral pharmaceutical manufacturing particularly important. Generic products must satisfy applicable requirements concerning active ingredient content, quality, stability, and bioequivalence where necessary. Manufacturers must carefully manage raw material quality, production validation, packaging, and distribution conditions. Changes in ingredient availability or production capacity can affect market supply. Competition also encourages manufacturers to improve operational efficiency without compromising pharmaceutical standards. Healthcare professionals may select treatments according to clinical suitability, availability, product labeling, and patient circumstances.
Loxoprofen Sodium Market Segmentation
By Types
Tablet: Tablet represents 72% of the Loxoprofen Sodium Market product segmentation and maintains the leading position because of established prescribing practices, convenient administration, and extensive generic manufacturing capabilities in approved markets. Oral loxoprofen sodium tablets are used for appropriate pain and inflammatory conditions according to local prescribing information. Tablets offer standardized drug content and packaging that can support routine dispensing through hospitals and retail pharmacies. Daiichi Sankyo Co., Ltd. has a longstanding association with the Loxonin brand, while Towa Pharmaceutical Co., Ltd. manufactures generic loxoprofen sodium tablets in Japan. Other companies participate in broader pharmaceutical manufacturing and distribution activities. Product quality depends on appropriate active ingredient specifications, manufacturing controls, dissolution characteristics, and stability testing.
Granule: Granule accounts for 4% of the Loxoprofen Sodium Market product segmentation and represents a specialized oral dosage category within the report's classification. Granulated formulations may provide alternative administration characteristics where suitable products are approved and available. Pharmaceutical granules require careful control of particle size, drug content uniformity, stability, and packaging. Their suitability depends on the specific product's authorization and instructions rather than a general assumption that granules are appropriate for particular age groups. Manufacturers evaluate flow characteristics and moisture sensitivity during production.
Capsule: Capsule represents 6% of the Loxoprofen Sodium Market product segmentation and includes specialized oral dosage presentations within the report's market framework. Capsules can offer alternative physical administration characteristics, although specific loxoprofen capsule availability depends on national product approvals. Manufacturers must ensure suitable drug content, capsule integrity, dissolution behavior, and stability. Products cannot be assumed to provide improved absorption or reduced adverse effects solely because they use a capsule format. The active ingredient's pharmacological risks remain important regardless of the oral dosage presentation.
Patch: Patch accounts for 18% of the Loxoprofen Sodium Market product segmentation and represents an important alternative to oral administration for selected localized musculoskeletal symptoms. Loxoprofen-containing topical patches deliver the active ingredient through the skin to support local analgesic and anti-inflammatory action. Product performance depends on drug concentration, adhesive formulation, patch dimensions, skin contact, and approved application instructions. Daiichi Sankyo's Loxonin S Tape range includes different patch formats used in Japan. During April 2026, the company's healthcare business introduced a compact version measuring 5 cm by 7 cm. The smaller design supports placement on selected body areas where a full-size patch may be less convenient. Topical therapy may be useful in appropriate circumstances, but skin reactions, systemic absorption, and relevant contraindications remain important.
By Applications
Pain Management: Pain Management accounts for 46% of the Loxoprofen Sodium Market application segmentation and maintains the leading position because of established use in appropriate musculoskeletal and other painful conditions. Loxoprofen sodium reduces pain through its effects on prostaglandin synthesis following metabolic activation. Clinicians may consider the medicine for selected acute or chronic symptoms where it is authorized and clinically appropriate. Treatment requirements vary according to pain location, severity, cause, patient age, medical history, and concurrent medication. Oral tablets remain important for systemic treatment, while topical patches provide an alternative for certain localized symptoms. Daiichi Sankyo's Loxonin portfolio demonstrates the availability of different administration formats in Japan. Healthcare professionals must consider treatment duration and use the lowest effective dose consistent with approved guidance.
Anti-inflammatory Treatment: Anti-inflammatory Treatment represents 27% of the Loxoprofen Sodium Market application segmentation and includes use in approved conditions involving inflammation-associated pain and tissue discomfort. Loxoprofen sodium belongs to the nonsteroidal anti-inflammatory medicine class and acts through inhibition of prostaglandin synthesis. Clinicians assess the underlying cause of inflammation before choosing symptomatic treatment. The medicine does not replace appropriate treatment of infections, autoimmune disease activity, or structural conditions requiring different interventions. Product availability and approved indications vary across countries. Oral and topical formulations have different administration characteristics and may be suitable for different clinical circumstances. Safety considerations remain important because nonsteroidal anti-inflammatory medicines can cause significant adverse effects.
Osteoarthritis Therapy: Osteoarthritis Therapy accounts for 15% of the Loxoprofen Sodium Market application segmentation and includes symptomatic management of selected patients experiencing osteoarthritis-related pain. Osteoarthritis can affect joint function and produce discomfort during movement or daily activities. Nonsteroidal anti-inflammatory medicines may be considered when appropriate, but treatment decisions depend on the affected joints, symptom severity, and patient-specific risks. Topical formulations can be relevant to certain localized joint symptoms where approved for the intended use. Oral formulations may be used under appropriate medical guidance, although prolonged treatment requires careful consideration of adverse effects. Loxoprofen sodium does not reverse the structural changes associated with osteoarthritis. Comprehensive management may also include exercise, physical rehabilitation, weight management, and other interventions.
Rheumatoid Arthritis Therapy: Rheumatoid Arthritis Therapy represents 12% of the Loxoprofen Sodium Market application segmentation and includes symptomatic treatment of pain and inflammation in patients with rheumatoid arthritis where use is authorized. Rheumatoid arthritis is an autoimmune inflammatory disease that can cause joint swelling, pain, and progressive damage. Nonsteroidal anti-inflammatory medicines may relieve symptoms, but they do not replace disease-modifying treatment intended to control the underlying inflammatory process. Clinical management requires specialist assessment and monitoring according to disease activity and patient circumstances. Oral loxoprofen formulations may be considered where clinically suitable, subject to local prescribing information. Healthcare professionals must evaluate gastrointestinal, renal, and cardiovascular risks, particularly when patients receive multiple medicines.
Loxoprofen Sodium Market Regional Outlook
North America
North America represents 14% of the report's analytical Loxoprofen Sodium Market regional allocation, although the figure is not a verified measure of approved commercial sales in the United States. The regional market requires careful interpretation because loxoprofen sodium does not have an established FDA-approved marketing pathway for routine United States use. Pharmaceutical manufacturers considering North American availability must satisfy applicable regulatory requirements before distributing products. The United States maintains extensive pain management services and research infrastructure, but demand for anti-inflammatory treatment should not automatically be equated with loxoprofen-specific utilization. Canada also has its own pharmaceutical authorization system. Commercial opportunities depend on documented product approvals and suitable distribution arrangements.
North American pharmaceutical development increasingly emphasizes evidence-based product assessment and appropriate safety monitoring. Tablet represents 72% of global analytical product demand, demonstrating the importance of oral pharmaceutical formulations in markets where the medicine is authorized. Companies must establish relevant quality information and clinical evidence before introducing products into additional jurisdictions. Differences between national regulations can influence development costs and timelines. Continued attention to safe and effective analgesic treatment supports the broader therapeutic environment.
Europe
Europe accounts for 20% of the report's analytical Loxoprofen Sodium Market regional allocation, but this figure should be distinguished from verified loxoprofen-specific sales across European countries. Pharmaceutical authorization and commercial availability vary by jurisdiction. Germany, France, Italy, the United Kingdom, and other European markets maintain established healthcare systems and demand for anti-inflammatory treatment, although that demand does not establish widespread loxoprofen prescribing. Manufacturers seeking regulatory authorization must provide appropriate evidence concerning quality, safety, and therapeutic use. Competition from established nonsteroidal anti-inflammatory products influences market opportunities. Pharmaceutical companies increasingly emphasize responsible prescribing and product information.
European drug development increasingly emphasizes safety evaluation and pharmaceutical quality standards. Anti-inflammatory Treatment represents 27% of global analytical application demand, highlighting the importance of this therapeutic category in markets where loxoprofen sodium is available. Regulatory review determines whether specific products can be marketed and for which indications. Manufacturers must also establish appropriate pharmacovigilance arrangements. Continued innovation in pharmaceutical formulation supports opportunities for clinically justified products.
Asia-Pacific
Asia-Pacific accounts for 58% of the Loxoprofen Sodium Market regional segmentation and maintains the leading position because of established prescribing practices, pharmaceutical manufacturing capabilities, and recognized product availability in Japan and selected neighboring countries. Japan remains particularly important because loxoprofen sodium has a longstanding history of use across prescription and selected over-the-counter products. Daiichi Sankyo Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., and Nippon Chemiphar Co., Ltd. participate in different parts of Japan's pharmaceutical environment. The region includes extensive generic manufacturing and pharmacy distribution capabilities. Product availability and approved indications differ among individual Asian markets. Continued demand for appropriate musculoskeletal symptom management supports regional leadership.
Asia-Pacific product development experienced an important event during April 2026 when Daiichi Sankyo's healthcare business introduced Loxonin S Tape mini in Japan. The compact product measures 5 cm by 7 cm and is intended for convenient use on smaller affected areas. Patch formulations represent 18% of analytical global product demand, illustrating commercial interest in topical alternatives to conventional oral treatment. Manufacturers increasingly emphasize appropriate labeling, application convenience, and consistent medicine quality. Continued development of established pharmaceutical brands supports regional competitiveness.
Middle East and Africa
Middle East and Africa represents 5% of the report's analytical Loxoprofen Sodium Market regional allocation and offers limited, jurisdiction-dependent opportunities associated with pharmaceutical distribution and broader pain management demand. Gulf countries maintain advanced healthcare facilities, while African markets display varying levels of medicine availability and regulatory infrastructure. Loxoprofen sodium cannot be assumed to have approval across the region because pharmaceutical marketing authorizations differ among countries. Manufacturers considering distribution must evaluate applicable product registration requirements and approved indications. Healthcare professionals select anti-inflammatory treatments according to national formularies and patient needs. Import arrangements and manufacturing compliance can influence availability.
Regional pharmaceutical development increasingly emphasizes safe medicine supply and regulatory oversight. Pain Management represents 46% of analytical global application demand, demonstrating the importance of symptomatic treatment within approved loxoprofen markets. Healthcare providers must evaluate patient-specific risks when considering nonsteroidal anti-inflammatory medicines. Distribution partners increasingly prioritize dependable pharmaceutical quality and clear product information. Continued investment in healthcare infrastructure supports the broader treatment environment.
Rest of World
Rest of World represents 3% of the report's analytical Loxoprofen Sodium Market regional allocation and includes selected territories outside the principal geographic classifications. Latin American markets maintain diverse pharmaceutical regulatory systems and established demand for pain management medicines, although loxoprofen-specific availability must be confirmed country by country. Pharmaceutical companies evaluating market entry must consider approval procedures, product labeling, manufacturing compliance, and distribution requirements. Competition from already authorized anti-inflammatory medicines can influence commercial potential. Healthcare providers increasingly emphasize responsible use and recognition of treatment-related adverse effects. Continued development of pharmaceutical services supports potential opportunities.
Regional product opportunities depend on documented medicine availability and established clinical demand. Osteoarthritis Therapy accounts for 15% of global analytical application demand, illustrating the role of musculoskeletal symptom management within the report's framework. Healthcare professionals must consider individual treatment requirements and relevant clinical guidelines. Manufacturers seeking expansion require appropriate regulatory submissions and dependable pharmaceutical supply arrangements. Continued attention to patient safety and medicine quality influences regional development.
List of Top Loxoprofen Sodium Market Companies
- Daiichi Sankyo Co., Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Nichia Corporation
- Taisho Pharmaceutical Holdings Co., Ltd.
- Towa Pharmaceutical Co., Ltd.
- Shionogi & Co., Ltd.
- Eisai Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Nippon Chemiphar Co., Ltd.
Top 2 Companies with Highest Market Share
- Daiichi Sankyo Co., Ltd.: Daiichi Sankyo Co., Ltd. holds 24% of the selected analytical competitive allocation, reflecting the established position of its Loxonin brand and its longstanding association with the development of loxoprofen sodium. The company maintains pharmaceutical research and development capabilities, while its healthcare business markets relevant oral and topical products in Japan. During March 2026, Daiichi Sankyo Healthcare announced Loxonin S Tape mini, which became available in April.
- Taisho Pharmaceutical Holdings Co., Ltd.: Taisho Pharmaceutical Holdings Co., Ltd. accounts for 18% of the selected analytical competitive allocation, reflecting its established Japanese consumer healthcare presence and broader pharmaceutical distribution capabilities. The company participates in pain management and other self-care categories through its pharmaceutical operations.
Investment Analysis and Opportunities
Investment opportunities in the Loxoprofen Sodium Market increasingly concentrate on reliable pharmaceutical manufacturing, patient-oriented topical formulations, and improved product quality. Tablet accounts for 72% of analytical product demand, making consistent oral formulation production an important commercial priority in approved markets. Manufacturers increasingly invest in pharmaceutical quality systems, raw material qualification, stability testing, and production efficiency. Generic companies can strengthen competitiveness through dependable supply and accurate product documentation. Product development may also address packaging convenience and pharmacy dispensing requirements.
Additional investment opportunities are emerging through topical product design and convenient application formats. Patch represents 18% of analytical product demand, highlighting opportunities for improvements in adhesive materials, patch flexibility, and administration convenience. Daiichi Sankyo's April 2026 introduction of a compact loxoprofen sodium patch demonstrates how established pharmaceutical products can be differentiated through physical design. Manufacturers may investigate new packaging arrangements and improved handling characteristics, subject to suitable quality and regulatory assessment.
New Product Development
New product development in the Loxoprofen Sodium Market increasingly emphasizes improved topical administration, product convenience, and reliable pharmaceutical quality. Patch formulations represent 18% of market demand, encouraging manufacturers to investigate compact patch dimensions, suitable adhesives, and packaging designed for easier handling. Daiichi Sankyo Healthcare launched Loxonin S Tape mini in Japan on April 15, 2026, providing a smaller format for selected localized painful areas. The product reflects attention to consumer preferences within an established anti-inflammatory medicine category. Manufacturers must validate formulation stability, drug delivery characteristics, and skin compatibility when introducing new patch products.
Another important development area involves improved generic medicine manufacturing and pharmacy handling technologies. Tablet represents 72% of analytical product demand, highlighting the importance of established oral formulations. Towa Pharmaceutical Co., Ltd. continues developing pharmaceutical manufacturing and packaging systems across its broader generic portfolio. During September 2026, the company announced recognition of its MEKUREL packaging technology, designed to simplify selected pharmacy dispensing activities. This development was not a new loxoprofen formulation, but it demonstrates innovation relevant to established tablet distribution and handling.
Five Recent Developments
- January 2026 – Fangsheng Receives Loxoprofen Gel Patch Approval: Fangsheng Pharmaceutical announced that its subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical, received Chinese regulatory approval for a loxoprofen sodium gel patch. The product is intended for anti-inflammatory and pain-relief applications involving osteoarthritis, muscle pain, and post-traumatic swelling.
- April 2026 – Daiichi Sankyo Launches Compact Loxonin Patch: Daiichi Sankyo Healthcare introduced Loxonin S Tape mini in Japan on April 15, 2026. The topical product contains loxoprofen sodium hydrate and features a compact 5 cm by 7 cm design intended for convenient application to smaller affected areas.
- April 2026 – Nanjing Hai Jing Gains Oral Solution Approval: Nanjing Hai Jing Pharmaceutical received Chinese regulatory approval on April 14, 2026, for a loxoprofen sodium oral solution containing 60 mg per 10 mL. The approval adds an oral liquid dosage form to the company's pharmaceutical portfolio.
- August 2026 – Fuyuan Pharmaceutical Secures Loxoprofen Patch Registration: Beijing Fuyuan Pharmaceutical announced Chinese regulatory approval for loxoprofen sodium patches in two strengths, 50 mg and 100 mg. The registrations support expansion of its prescription topical pain-management portfolio.
- August 2026 – Frontier Biotechnologies Obtains Loxoprofen Patch Approval: Frontier Biotechnologies announced that its subsidiary, Qihe Frontier Biotechnologies Pharmaceutical, received Chinese regulatory approval for its FB3002 loxoprofen sodium patch. The product uses a hot-melt adhesive formulation developed for localized musculoskeletal pain management.
Report Coverage of Loxoprofen Sodium Market
The Loxoprofen Sodium Market report provides a qualitative assessment of pharmaceutical formulations, therapeutic application categories, manufacturing processes, and competitive conditions. Product coverage includes tablets, granules, capsules, and patches, considering administration methods, formulation characteristics, stability, and quality requirements. Application analysis examines pain management, anti-inflammatory treatment, osteoarthritis therapy, and rheumatoid arthritis therapy within relevant regulatory contexts. The study explores oral dosage manufacturing, topical delivery systems, packaging, generic product availability, and quality assurance. Market dynamics coverage addresses treatment demand, regulatory requirements, formulation development opportunities, and product safety considerations.
Regional coverage includes North America, Europe, Asia-Pacific, Middle East and Africa, and Rest of World, examining regulatory environments, manufacturing infrastructure, distribution channels, and market accessibility. Investment analysis considers generic manufacturing, topical formulation research, quality control, and supply continuity. Product development coverage explores patch design, administration convenience, packaging improvements, and manufacturing efficiency. Competitive assessment examines product portfolios, brand positioning, production capabilities, and regulatory preparedness. The report also reviews relevant industry announcements, distinguishing developments directly involving loxoprofen sodium from broader pharmaceutical activities to assess factors influencing product availability, formulation strategies, and market competitiveness.
Loxoprofen Sodium Market Report Coverage
| REPORT COVERAGE | DETAILS |
|---|---|
| Market Size Value In | USD 1346.06 Million in 2026 |
| Market Size Value By | USD 2319.65 Million by 2035 |
| Growth Rate | CAGR of 6.23% from 2026-2035 |
| Forecast Period | 2026 - 2035 |
| Base Year | 2025 |
| Historical Data Available | Yes |
| Regional Scope | Global |
| Segments Covered |
By Type
Tablet | Granule | Capsule | Patch
By Application
Pain Management | Anti-inflammatory Treatment | Osteoarthritis Therapy | Rheumatoid Arthritis Therapy
|
Frequently Asked Questions
The global Loxoprofen Sodium market is expected to reach USD 2319.65 Million by 2035.
The Loxoprofen Sodium Market is expected to exhibit a CAGR of 6.23% by 2035.
Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nichia Corporation, Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Chemiphar Co., Ltd..
In 2026, the Loxoprofen Sodium market value stood at USD 1346.06 Million.
Our
Clients